COMMD1 and ovarian carcinoma: Given the nuclear expression of COMMD1 in a subgroup of ovarian cancer patients (Fig 1C) and increased cisplatin sensitivity of ovarian A2780 cancer cells with elevated nuclear COMMD1 levels (Fig 2C), we explored whether the expression and subcellular localization of COMMD1 in ovarian tumors correlated with patient outcome.